glp-1 lawsuit news Mounjaro - July 2026 Update GLP-1 Lawsuit Attorneys
Description
The SELECT trial, as noted earlier, went a step further it tested Wegovy in overweight/obese individuals with cardiovascular disease (but without diabetes) and found a 20% reduction in heart attacks, stroke, or CV death ( [67] )
15 In terms of their overall effect, these changes seem not worthwhile
Theres no single right answer for everyone
A 20-pound loss is more realistic after 4+ months on weight loss medication
They can help determine the most effective medication based on your overall medical condition and potential drug interactions
It is not approved for type 2 diabetes management under the Zepbound brand name, though the same active ingredient is marketed as Mounjaro for diabetes treatment
